Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3671-3680 Newer>

The Motley Fool May 3, 2007 Billy Fisher	Optimism for OSI With Tarceva sales growing across the board and the potential for new uses on the horizon, coupled with a shrewd divestiture of an unprofitable product, the general outlook for OSI appears to be quite favorable. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	BioMarin Moves Ahead The drug developer released first-quarter financial results. Even though BioMarin is not yet profitable, its management team has proven capable in all areas of drug development, from the clinical stage to commercialization. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool May 2, 2007 Mike Havrilla	Consider Cortex New findings may give Cortex's ADHD drug the lift it needs. The news represents an excellent opportunity for speculative biotech investors
The Motley Fool May 2, 2007 Rich Duprey	Cynosure Sure Looks Good Aesthetic-laser maker reports record results on strength of new laser offerings. Investors, take note.
The Motley Fool May 2, 2007 Mike Havrilla	An Eye-Opening Potential Acquisition The Biotech firm Inspire should consider buying drug-development partner InSite Vision.
The Motley Fool May 1, 2007 Brian Lawler	Northfield Delays the Inevitable Northfield announces a delay in the analysis of a clinical trial for its drug candidate. Investors, take note.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
<Older 3671-3680 Newer> Return to current articles.